Novo Holdings, the controlling shareholder of drug maker Novo Nordisk, said on Wednesday that its total income and investment ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Novo Nordisk's (NYSE: NVO) is famous and celebrated for its cutting-edge obesity medication. Its U.S.-traded American ...

Learn more about whether Corcept Therapeutics Incorporated or Novo Nordisk A/S is a better investment based on AAII's A+ ...

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Eli Lilly's stock has demonstrated remarkable resilience this year, gaining approximately 6% while Danish competitor Novo ...